Brain Navi Biotechnology Co., Ltd., a brain surgery robotic company, is launching “zero-contact” medical stations in hospitals across Taiwan, fully protect medical staff and patients from the cross-infection of “highly contagious diseases.” The biggest risk of infection for medical staff is during intubation, nasal swabbing, and personal protective equipment (PPE) removal, says Dr. Jerry Chen, the Brain Navi CEO. He adds that “Since the SARS crisis in Asia 17 years ago, there was no advancement in the protection technology for medical staff. How could medical staff protect us if they are not well protected in the first place?”. As a physician himself with a full understanding of the frontline medical staff’s anxiety, this motivates Dr. Chen to reimagine testing for infectious diseases using robotics, enabling zero-contact between medical staff and patients.
The Zero-Contact Medical Station with robotics technology is creating a new normal of Covid-19 testing in Taiwan. Medical staff and patients stay in an isolated chamber with safety features, including HEPA filter, UVC lamps, a ventilation system, and a negative 8 Pa air pressure. Under medical staff’s control and supervision, a Nasal Swab Robot performs the nasopharynx specimen collection. This allows the medical staff to achieve nasal swabbing without patient contact and eliminates the need to wear a PPE. Nasal Swab Robot just obtained the CE mark with Class I.
The Zero-Contact Medical Station achieves zero-contact swabbing and pipetting tasks for lab technicians. After swabbing, an automated robot will then pipette the collected specimen and prepare an essay for PCR diagnosis. The robotic systems are integrated with Roche’s RT-PCR device allowing automatic and efficient process. The entire testing process from robot’s collection to result generation can be done in 25 minutes.
Through robotics automation and consolidation of PCR lab and diagnosis in one medical station, the Zero-Contact Medical Station protects medical staff and minimizes precious staffing, improves lab testing capacity, and reduces transport and reporting time.
The zero-contact features and rapid PCR testing with minimal staffing make this station an ideal solution for large-scale testing at public venues such as cruise ships, stadiums, and airports, allowing your country to reopen the economy or commence the travel bubble with safety measures. To find out more about the Zero-Contact Medical Station, please visit our website https://brainnavi.com/zerocontactstation/.
In an effort to treat patients currently suffering from COVID-19, researchers from Feinstein Institutes are collaborating on new clinical studies with biopharmaceutical leaders Gilead Sciences, Regeneron and Sanofi
The Feinstein Institutes for Medical Research, the research arm of Northwell Health, announced today the enrollment of three clinical trials in the ongoing effort to combat COVID-19, the novel coronavirus.
Feinstein Institutes researchers are teaming up with Gilead Sciences, Regeneron Pharmaceuticals and Sanofi to identify effective treatments for patients currently hospitalized in moderate and severe conditions with COVID-19. The goal is to improve recovery and speed discharge from hospitals. The three Feinstein Institutes trials are offered to patients already admitted to Northwell Health hospitals with moderate to severe COVID-19. The trials are not currently available to the general public.
“We’ve joined with three outstanding companies to immediately begin clinical trials for patients now suffering from COVID-19 and are determined to do all we can to stop the virus in its tracks,” said Michael Dowling, president and CEO of Northwell Health.
While there is a nationwide push for an expedited Food and Drug Administration (FDA) approval process of these and other experimental COVID-19 therapies, Northwell Health and the Feinstein Institutes prioritize the safety of patients. The process of these formal trials will lead to accurate testing of these novel drugs prior to mainstream use.
With Gilead, the Feinstein Institutes will conduct two trials looking at the safety and efficacy of remdesivir (RDV), an investigational antiviral drug, designed to reduce the intensity and duration of COVID-19 in hospitalized patients. RDV has demonstrated positive effects on other viral pathogens such as MERS and SARS in vitro and in animal models. The first trial can accommodate up to 400 severe cases of COVID-19 globally and is a randomized study of two different durations of treatment with RDV, delivered intravenously. Researchers will look at clinically relevant endpoints in patients with severe manifestations of disease. The lead investigator on this study is Marcia Epstein, MD, Feinstein Institutes researcher and an infectious disease expert.
The other RDV trial in collaboration with Gilead is also a phase 3 study that will assess two different durations of treatment with RDV as compared to current standard of care in up to 600 patients with moderate COVID-19 globally. Researchers will look at clinical endpoints and time to discharge. The lead investigator on this study is Prashant Malhotra, MD, assistant professor in the Institute of Health Innovations & Outcomes Research at Feinstein, and an infectious disease expert.
In collaboration with Regeneron Pharmaceuticals and Sanofi, the Feinstein Institutes will conduct an adaptive randomized trial for approximately 400 severe or critical patients being hospitalized for the virus in multiple sites across the US. It will look at the safety and efficacy of sarilumab, a human antibody that may prevent the activity of a specific cytokine called interleukin-6 (IL-6) that is thought to be important in the development of complications of severe pneumonia in some COVID-19 patients.
The role of IL-6 is supported by preliminary data from a Chinese trial and based on those results which showed rapid reductions in fever in all patients, China recently updated its COVID-19 treatment guidelines and approved the use of that IL-6 inhibitor to treat patients with severe or critical disease. The study that the Feinstein Institutes will participate in is the first controlled trial in the U.S. to evaluate the effect of IL-6 inhibition prospectively in COVID-19 patients. The lead investigator on this study is Negin Hajizadeh, MD, assistant professor in the Institute of Health Innovations & Outcomes Research at Feinstein, and a pulmonary and critical care physician.
“As history has shown from past pandemics, medical research will lead in our nation’s ability to reverse the fatal spread of viruses,” said Kevin J. Tracey, MD, president and CEO of the Feinstein Institutes. “By teaming up with these outstanding pharmaceutical leaders, our researchers have the opportunity to help beat the Coronavirus by delivering cutting-edge care through clinical research at our Northwell Health hospitals.”
About the Feinstein Institutes
The Feinstein Institutes for Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 2,500 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine. For more information about how we produce knowledge to cure disease, visit feinstein.northwell.edu.
About Northwell Health
Northwell Health is New York State’s largest health care provider and private employer, with 23 hospitals, about 750 outpatient facilities and more than 13,600 affiliated physicians. We care for over two million people annually in the New York metro area and beyond, thanks to philanthropic support from our communities. Our 70,000 employees – 16,000-plus nurses and 4,000 employed doctors, including members of Northwell Health Physician Partners – are working to change health care for the better. We’re making breakthroughs in medicine at the Feinstein Institutes for Medical Research. We’re training the next generation of medical professionals at the visionary Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and the Hofstra Northwell School of Graduate Nursing and Physician Assistant Studies. For information on our more than 100 medical specialties, visit Northwell.edu and follow us @NorthwellHealth on Facebook, Twitter, Instagram and LinkedIn.
Saint-Gobain Life Sciences, an industry leader in material science-based solutions for cell and gene therapy manufacturing, today launched a new cell culture bag designed specifically for T cell derived therapies.
T cell based therapies are revolutionizing the approach to treating cancer. Harnessing the patient’s own immune system by isolating their T cells and engineering them to elicit an immune response is emerging as a preferred manufacturing practice. As the industry continues the advancement of these therapies, process efficiency becomes paramount to the success of delivering affordable therapies to patients.
Building upon the VueLife® family of fluorinated ethylene propylene (FEP) based cell culture bags, VueLife® “HP” (high permeability) incorporates an innovative, patented laminate film layer that allows increased CO2 and O2 exchange versus other monolayer bag designs, yet maintains the scalability and process flexibility offered by a closed bag system. The increased permeability associated with the “HP” laminate layer was specifically designed for culturing cells requiring higher rates of respiration, such as T cells.
“The development of this product was in direct response to the market need for a cost effective culture vessel that provides efficient cell expansion in a scalable, closed system,” said Benjamin Le Quere, General Manager for the Saint-Gobain Life Sciences Bioprocess Solutions business unit. “VueLife® “HP” is an exciting result of the marrying of our expertise in material science with our knowledge in cell culture.”
The entire family of VueLife® cell culture bags utilize a common FEP fluid-contact layer. FEP creates an ideal environment for cell growth due to its gas permeability and liquid impermeability, while being biologically and chemically inert.
ABOUT SAINT-GOBAIN LIFE SCIENCES
Dedicated to improving the quality of life, Saint-Gobain Life Sciences develops and manufactures high-performance components and integrated solutions that touch a broad range of patient care, from the development of new therapeutic cancer treatments to biopharmaceutical production, on through to intravenous therapies for drug delivery.
Along with material science expertise and collaborative design services, our focus on global quality and regulatory affairs allow us to be the trusted partner to organizations reaching every part of the globe. Combining our technical expertise, global manufacturing capabilities and research and development resources, Saint-Gobain Life Sciences is dedicated to meeting the evolving needs of bioprocess, medical and pharmaceutical customers around the world. Saint-Gobain Life Sciences is part of Compagnie de Saint-Gobain.
Compagnie de Saint-Gobain designs, manufactures and distributes materials and solutions which are key ingredients in the wellbeing of each of us and the future of all. They can be found everywhere in our living places and our daily life: in buildings, transportation, infrastructure and in many industrial applications. They provide comfort, performance and safety while addressing the challenges of sustainable construction, resource efficiency and climate change. Saint-Gobain operates in 70 countries with more than 180,000 employees worldwide. The Company had €42.6 billion in sales in 2019.